mitoxantrone.Afteramedianfollow-uptimeof8.3years,themediansurvivalforallrandomizedpatientswas2.8years(95%CI,1.9-6.8years).Therewasnodifferenceindisease-freesurvival(DFS)betweenthe2regimens(P�.66).ThemedianDFSwas1.1years(95%CI,0.9-1.7years)forpatientsreceivingHiDACand1.0year(95%CI,0.9-1.3years)for...
The mean complete remission rate is lower than in the younger group (25-40%) and overall survival is much worse (less than 10% during 5 years) (8-12). There were few reports on extremely high rate of CR (76%,62%) in the patients over 60 years old, but they seem to be very ...
This could indicate that DOX-resistant cells have a lower dependency on folate cycle for survival than the other cell models. We found that our GSMMs could reproduce this behavior through partial inhibition of DHFR, where it was shown that DOX-resistant cells required a higher degree of ...
system. Generally, MDS patients have a poor prognosis, with a median overall survival of only 5 years. MDS patients who progressed to AML, have higher-risk MDS, with myeloblast count ≥ 20% and acquired/expanded abnormalities inTP53,RUNX1, orRASgenes [19]. Phenotypically, high-grade MD...
CR=complete remission; OS=overall survival. DA(7 + 3) 中位OS 4.6 months 8周死亡率 36% CR率 40%–50% 老年AML应是基于患者情况的综合治疗 预后差,生存期短;治疗药物选择应基于患者PS评分、老年合并症等情况进行综合治疗。 去甲基化治疗概述 1 老年AML治疗现状与挑战 2 去甲基化用于老年AML的临床获益...
t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subtype with a favorable prognosis, approximately
For cases where compounds failed to inhibit AML cell survival/proliferation, IC50 values were arbitrarily reported at the highest dose tested (10 μM). Additional materials and methods can be found in the supplemental Material. Results The global Leucegene cohort is composed of 68 CK and 347 ...
Median overall survival in the RP2D cohorts was 5.3 months (range, 0.2–17.6). The response rate was very high at 86% in patients with IDH2 mutation and 57% in patients with a RUNX1 mutation, but only 20% in patients with TP53 mutation [85]. MDM2 antagonists have been combined with ...
survival differences between t-AML and de novo AML patients. In our cohort, the differences in OS in favor of de novo AML reached beyond 15% after 5 years. This particularly affected patients who were younger than 60 years or were belonging to the ELN intermediate I/II and adverse risk ...
[57]. However, these results need to be confirmed in randomized prospective studies. We currently treat fitNPM1-mutated AML patients >60 but <75 years old with standard CHT, although outcome remains poor, independently ofFLT3status (3-year overall survival of 35%) [58]. Older eligible ...